

Kymriah[™] (tisagenlecleucel) - New indication

- On May 1, 2018, <u>Novartis announced</u> the FDA approval of <u>Kymriah (tisagenlecleucel)</u> for the
 treatment of adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of
 systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high
 grade B-cell lymphoma and DLBCL arising from follicular lymphoma.
 - Kymriah is not indicated for the treatment of patients with primary central nervous system lymphoma.
- Kymriah is also indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
- DLBCL is the most common form of non-Hodgkin lymphoma. For patients who relapse or don't respond to initial therapy, there are limited treatment options that provide durable responses, and the median life expectancy is approximately 6 months.
- The safety and efficacy of Kymriah in refractory DLBCL was evaluated in an open-label, single-arm trial in adults who had received ≥ 2 lines of chemotherapy or relapsed from hematopoietic stem cell transplantation. Following 2 to 11 days after completing lymphodepleting chemotherapy, Kymriah was administered as a single intravenous (IV) infusion. Bridging chemotherapy was permitted to control disease burden.
 - Complete response was achieved in 32% of patients (95% CI: 21.5%, 44.8%).
 - The median duration of response had not been reached at the time of analysis.
 - The overall response rate was 50% (95% CI: 37.6%, 62.4%).
- Kymriah carries a boxed warning for cytokine release syndrome and neurological toxicities.
 - Kymriah is available through a Risk Evaluation and Mitigation Strategy (REMS) program to inform and educate healthcare professionals about Kymriah's risks.
- The most common adverse reactions (> 20%) with Kymriah use in DLBCL patients were cytokine release syndrome, infections (pathogens unspecified), pyrexia, diarrhea, nausea, fatigue, hypotension, edema, and headache.
- In adult patients with DLBCL, Kymriah is provided as a single-dose of 0.6 to 6.0 x 10⁸ chimeric antigen receptor-positive viable T-cells for IV infusion.
 - Refer to the Kymriah drug label for dosing information in ALL.
- To ensure that eligible patients have access to Kymriah, Novartis continues to collaborate with the Centers for Medicare and Medicaid Services (CMS) on the creation of an appropriate value-based pricing approach.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.